soul trial oral semaglutide cardiovascular outcomes nejm 2025 results New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis 🔴Cardiovascular outcomes with semaglutide by

The future of GLP-1 therapy lies in this thoughtful integration of precise dosing strategies with comprehensive wellness approaches, always under careful medical guidance

While public health experts and climate scientists argue about whether we should rely on livestock production systems to meet the nutritional demands of a growing global population while tackling climate change, those who produce our foodthe average farmerare struggling financially (Wiggins et al., 2010)

If you miss a dose and it has been less than four days since your scheduled injection, take the missed dose as soon as you remember

Fluorescence intensity of DCF staining was analyzed on FL-1 (525 nm) using BD Accuri C6 software (BD Biosciences, San Jose, CA, USA)

By The Wondr Health Team Obesity and weight-related chronic conditions are one of the most pressing challenges in the modern workplace